Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BASEL, SWITZERLAND AND LONDON AND NEW YORK, JULY 23, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON THURSDAY, AUGUST 6, 2026, TO REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2026, AND PROVIDE A BUSINESS UPDATE.

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2026, AND PROVIDE BUSINESS UPDATE ON THURSDAY, AUGUST 6, 2026

DURHAM, N.C., JULY 23, 2026 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC.(NASDAQ:IMVT) TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2026 ON THURSDAY, AUGUST 6, 2026 BEFORE THE MARKET OPENS.

IMMUNOVANTTOREPORT FINANCIAL RESULTS FOR THEFIRSTQUARTER ENDEDJUNE30, 2026,AND PROVIDE BUSINESS UPDATEONTHURSDAY,AUGUST6, 2026

BASEL, SWITZERLAND AND LONDON AND NEW YORK, MAY 20, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH31, 2026, AND PROVIDED A BUSINESS UPDATE.

ROIVANT REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2026 AND PROVIDES BUSINESS UPDATE

DURHAM, N.C., MAY 11, 2026 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ:IMVT) TODAYANNOUNCEDTHAT IT WILLREPORT ITSFINANCIAL RESULTS FOR THEFOURTHQUARTER AND FISCAL YEAR ENDEDMARCH31, 2026, AND PROVIDE A BUSINESS UPDATEAT 8:00 A.M.

IMMUNOVANTTOREPORT FINANCIAL RESULTS FOR THEFOURTHQUARTER AND FISCAL YEAR ENDEDMARCH31, 2026,AND PROVIDE BUSINESS UPDATEONWEDNESDAY,MAY20, 2026

BASEL, SWITZERLAND AND LONDON AND NEW YORK, MAY 11, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON WEDNESDAY, MAY 20, 2026, TO REPORT ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2026, AND PROVIDE A BUSINESS UPDATE.

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2026 AND PROVIDE BUSINESS UPDATE ON WEDNESDAY, MAY 20, 2026

LICHEN PLANOPILARIS (LPP) IS A HIGHLY MORBID INFLAMMATORY SCALP DISORDER THAT CAUSES GENERALLY IRREVERSIBLE SCARRING HAIR LOSS, OFTEN ACCOMPANIED BY PROFOUND PAIN, ITCH, AND BURNING SENSATIONS; NO FDA-APPROVED THERAPIES EXIST FOR LPP, HIGHLIGHTING A CRITICAL UNMET THERAPEUTIC NEED LPP MARKS THE FOURTH INDICATION IN BREPOCITINIB'S EXPANDING LATE-STAGE DEVELOPMENT PROGRAM MULTIPLE LINES OF EVIDENCE, INCLUDING STRONG MECHANISTIC RATIONALE AND CLINICALLY MEANINGFUL RESULTS IN AN INVESTIGATOR-INITIATED PLACEBO-CONTROLLED STUDY OF BREPOCITINIB IN LPP, SUPPORT RAPID DEVELOPMENT OF BREPOCITINIB IN THIS INDICATION A SEAMLESS PHASE 2B/3 POTENTIALLY REGISTRATIONAL TRIAL OF BREPOCITINIB IN LPP ENROLLED ITS FIRST SUBJECTS IN MARCH 2026 IMMUNOVANT'S PHASE 3 STUDIES OF BATOCLIMAB IN THYROID EYE DISEASE (TED) EACH FAILED TO MEET THEIR PRIMARY ENDPOINT; SAFETY RESULTS WERE CONSISTENT WITH PREVIOUS FINDINGS PATIENTS IN THE TED STUDIES DEMONSTRATED GREATER LEVELS OF PROPTOSIS IMPROVEMENT FROM BASELINE AFTER THE INITIAL 12-WEEK HIGH-DOSE PERIOD THAN AFTER THE FOLLOWING 12-WEEK LOW-DOSE PERIOD, SUPPORTING THE BENEFIT OF DEEPER IGG SUPPRESSION. THE HYPERTHYROID PATIENTS IN THE TED STUDIES SHOWED SIMILAR RESPONSE RATES OF THYROID HORMONE NORMALIZATION TO THOSE SEEN IN THE BATOCLIMAB PHASE 2 STUDY IN GRAVES' DISEASE IMMUNOVANT REMAINS FOCUSED ON RAPID ADVANCEMENT OF IMVT-1402 IN MULTIPLE INDICATIONS ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, APRIL 2, 2026, AT 8:00 A.M.

ROIVANT ANNOUNCES EXPANSION OF BREPOCITINIB DEVELOPMENT PROGRAM WITH NEW PHASE 2B/3 TRIAL IN LICHEN PLANOPILARIS (LPP) AND PHASE 3 STUDY RESULTS FOR BATOCLIMAB IN THYROID EYE DISEASE (TED)

LICHEN PLANOPILARIS (LPP) IS A HIGHLY MORBID INFLAMMATORY SCALP DISORDER THAT CAUSES GENERALLY IRREVERSIBLE SCARRING HAIR LOSS, OFTEN ACCOMPANIED BY PROFOUND PAIN, ITCH, AND BURNING SENSATIONS; NO FDA-APPROVED THERAPIES EXIST FOR LPP, HIGHLIGHTING A CRITICAL UNMET THERAPEUTIC NEED LPP MARKS THE FOURTH INDICATION IN BREPOCITINIB'S EXPANDING LATE-STAGE DEVELOPMENT PROGRAM MULTIPLE LINES OF EVIDENCE, INCLUDING STRONG MECHANISTIC RATIONALE AND CLINICALLY MEANINGFUL RESULTS IN AN INVESTIGATOR-INITIATED PLACEBO-CONTROLLED STUDY OF BREPOCITINIB IN LPP, SUPPORT RAPID DEVELOPMENT OF BREPOCITINIB IN THIS INDICATION A SEAMLESS PHASE 2B/3 POTENTIALLY REGISTRATIONAL TRIAL OF BREPOCITINIB IN LPP ENROLLED ITS FIRST SUBJECTS IN MARCH 2026 DURHAM, N.C., APRIL 02, 2026 (GLOBE NEWSWIRE) -- PRIOVANT TODAY ANNOUNCED A NEW PHASE 2B/3 CLINICAL PROGRAM FOR BREPOCITINIB IN LICHEN PLANOPILARIS (LPP), A HIGHLY MORBID INFLAMMATORY SCALP DISORDER AFFECTING APPROXIMATELY 100,000 ADULTS IN THE UNITED STATES.

PRIOVANT EXPANDS BREPOCITINIB DEVELOPMENT PROGRAM WITH NEW PHASE 2B/3 TRIAL IN LICHEN PLANOPILARIS (LPP)

DURHAM, N.C., MARCH 28, 2026 (GLOBE NEWSWIRE) -- PRIOVANT THERAPEUTICS, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TARGETED THERAPEUTICS IN AUTOIMMUNE DISEASE, ANNOUNCED TODAY THE PUBLICATION OF RESULTS FROM THE PHASE 3 VALOR TRIAL EVALUATING BREPOCITINIB IN ADULTS WITH DERMATOMYOSITIS (DM) IN THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM).

NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES POSITIVE PHASE 3 VALOR TRIAL RESULTS OF BREPOCITINIB IN DERMATOMYOSITIS

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ARBUTUS ANNOUNCES THAT IT IS CURRENTLY EVALUATING A RETURN OF CAPITAL TO SHAREHOLDERS FOR THE THIRD QUARTER OF CALENDAR YEAR 2026, IN CONJUNCTION WITH THE UPFRONT PAYMENT ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND VANCOUVER, BRITISH COLUMBIA, MARCH 03, 2026 (GLOBE NEWSWIRE) -- GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT SCIENCES LTD.

GENEVANT SCIENCES AND ARBUTUS BIOPHARMA ANNOUNCE $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ROIVANT'S BOARD OF DIRECTORS HAS APPROVED A $1 BILLION SHARE REPURCHASE PROGRAM, INCLUSIVE OF THE $500 MILLION AUTHORIZATION THAT WAS APPROVED IN JUNE 2025 ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND LONDON AND NEW YORK, MARCH 03, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT, AND ARBUTUS BIOPHARMA CORPORATION (NASDAQ: ABUS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON INFECTIOUS DISEASE, HAVE ENTERED INTO A $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA, INC. TO RESOLVE ALL U.S. AND INTERNATIONAL ENFORCEMENT ACTIONS INVOLVING MODERNA'S UNAUTHORIZED USE OF GENEVANT'S AND ARBUTUS' LNP DELIVERY TECHNOLOGY IN ITS COVID-19 VACCINES, INCLUDING S

Roivant Sciences Ltd.

ROIV

Price

Financial Reports

No items found.

Press Releases

Roivant Sciences Ltd.

ROIV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ROIV